LA JOLLA, Calif., Sept. 25 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced a one year extension of its research agreement with Eisai Co., Ltd. that was entered into on October 1, 2005. The extension marks the continuation of Eisai's support of Alzheimer's disease research at TorreyPines since 2001. This agreement, focusing on the discovery of Alzheimer's disease targets using whole-genome family-based association screening, is one of two TorreyPines discovery collaborations with Eisai in the field of Alzheimer's disease research. In a separate agreement, Eisai and TorreyPines are collaborating on the discovery of novel compounds to treat Alzheimer's disease.
The goal of the genetics research collaboration is to identify and validate genes associated with Alzheimer's disease as potential pharmaceutical targets. Under the terms of the agreement and in connection with the extension, TorreyPines will receive an upfront payment and continued research funding in support of the program for an additional year. In return, Eisai will continue to have exclusive rights of first negotiation and refusal for gene targets discovered and validated through the research.
"We are pleased that Eisai, a leader in Alzheimer's disease research, has elected to continue their long-standing support of our genetics discovery program," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "The extension of our collaboration with Eisai not only validates the importance of this research, but also moves us one step closer to our goal of discovering new therapies for patients suffering from Alzheimer's disease."
The genetics research will be performed at TorreyPines in c
|SOURCE TorreyPines Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved